Homozygous Familial Hypercholesterolemia (HoFH) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030


 Homozygous familial hypercholesterolemia (HoFH) is a genetic disorder that causes severe elevations in low-density lipoproteins cholesterol (LDL-C) and total cholesterol. Those with HoFH have a very high chance of premature coronary artery disease. Familial hypercholesterolemia is a deficiency or absence of the LDL-C receptors. It can also be caused by mutations of the apolipoprotein B-100 (apoB-100) binding site on LDL-C receptors, PCSK9, and LDLRAP1. The LDLR gene is located on the short arm of chromosome 19.6 LDL-C receptors are responsible for about 70% of the uptake of circulating LDL-C molecules into the liver. Reductions in the number of LDL-C receptors lead to an accelerated deposition of cholesterol on the walls of arteries. The arteries then harden and narrow and reduce the flow of blood. This reduction in blood flow can lead to cardiovascular diseases like stroke and myocardial infarction.

·       In the year 2020, the estimated prevalence of HoFH in the United States was around 1 to 2.5 cases per 160,000 to 300,000 persons, a significant increase from previous estimates.

 

The competitive landscape of Homozygous Familial Hypercholesterolemia (HoFH) includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Homozygous Familial Hypercholesterolemia (HoFH) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Homozygous Familial Hypercholesterolemia (HoFH) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Homozygous Familial Hypercholesterolemia (HoFH) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Evinacumab      Regeneron Pharmaceuticals      Phase 3

2          IBI306  Innovent Biologics (Suzhou) Co. Ltd.      Phase 3

3          AK102  Akeso   Phase 2

4          Inclisiran           Novartis Pharmaceuticals          Phase 3

5          evolocumab (AMG 145) Amgen  Phase 3

6          ALN-PCSSC     The Medicines Company           Phase 2

7          Lomitapide        Amryt Pharma   Phase 3

8          lomitapide         Aegerion Pharmaceuticals, Inc.  Phase 3

9          Rosuvastatin     AstraZeneca     Phase 3

10        lerodalcibep and evolocumab     LIB Therapeutics LLC    Phase 3

Continued

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more